{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:37:34Z","timestamp":1786541854693,"version":"build-2736575974"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL007734"],"award-info":[{"award-number":["5T32HL007734"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["2T32DK007754-22"],"award-info":[{"award-number":["2T32DK007754-22"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32HL007734"],"award-info":[{"award-number":["5T32HL007734"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Richard and Sandra Cummings Research Fellowship of the Beth Israel Deaconess Medical Center Department of Ophthalmology"},{"name":"Michael Plantevin"},{"name":"The Monte J. Wallace Ophthalmology Chair in Retina"},{"DOI":"10.13039\/100014895","name":"Open Philanthropy Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020392","name":"Good Ventures Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020392","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Boston Children\u2019s Hospital Vascular Biology Program"},{"name":"The Boston Children\u2019s Hospital Surgical Foundation"},{"name":"The Hannah Lillie Fund"},{"name":"The Maisie Ellis & Friends Fund"},{"name":"The Luke Raymond Celaya Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-55553-2","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T09:26:55Z","timestamp":1780392415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhibition of runt related transcription factor 1 with Ro24-7429 improves lung function in experimental models of idiopathic pulmonary fibrosis"],"prefix":"10.1038","volume":"16","author":[{"given":"Thomas I.","family":"Hirsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William P.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savas T.","family":"Tsikis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said Jose","family":"Arevalo-Alquichire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan A.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim W.","family":"Barake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey L.","family":"Gunawan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Vanderleest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruvi","family":"Vijikumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeysson","family":"Sanchez-Suarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Fligor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah Z.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Shei","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikayla","family":"Quigley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Kamiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edy Y.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"O\u2019Hare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Lennikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo A.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Puder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,2]]},"reference":[{"key":"55553_CR1","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","volume":"183","author":"G Raghu","year":"2011","unstructured":"Raghu, G. et al. An official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Respir Crit. Care Med. 183, 788\u2013824. https:\/\/doi.org\/10.1164\/rccm.2009-040GL (2011).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"55553_CR2","doi-asserted-by":"publisher","unstructured":"Barratt, S. L., Creamer, A., Hayton, C. & Chaudhuri, N. Idiopathic Pulmonary Fibrosis (IPF): An Overview. J. Clin. Med. 7 https:\/\/doi.org\/10.3390\/jcm7080201 (2018).","DOI":"10.3390\/jcm7080201"},{"key":"55553_CR3","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1111\/crj.13466","volume":"16","author":"DS Glass","year":"2022","unstructured":"Glass, D. S. et al. Idiopathic pulmonary fibrosis: Current and future treatment. Clin. Respir J. 16, 84\u201396. https:\/\/doi.org\/10.1111\/crj.13466 (2022).","journal-title":"Clin. Respir J."},{"key":"55553_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2147\/clep.S54815","volume":"5","author":"B Ley","year":"2013","unstructured":"Ley, B. & Collard, H. R. Epidemiology of idiopathic pulmonary fibrosis. Clin. Epidemiol. 5, 483\u2013492. https:\/\/doi.org\/10.2147\/clep.S54815 (2013).","journal-title":"Clin. Epidemiol."},{"key":"55553_CR5","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/s2213-2600(14)70101-8","volume":"2","author":"G Raghu","year":"2014","unstructured":"Raghu, G. et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2, 566\u2013572. https:\/\/doi.org\/10.1016\/s2213-2600(14)70101-8 (2014).","journal-title":"Lancet Respir Med."},{"key":"55553_CR6","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer, D. J. & Martinez, F. J. Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 378, 1811\u20131823. https:\/\/doi.org\/10.1056\/NEJMra1705751 (2018).","journal-title":"N. Engl. J. Med."},{"key":"55553_CR7","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1021\/acs.jmedchem.6b00935","volume":"60","author":"YM Liu","year":"2017","unstructured":"Liu, Y. M., Nepali, K. & Liou, J. P. Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets. J. Med. Chem. 60, 527\u2013553. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00935 (2017).","journal-title":"J. Med. Chem."},{"key":"55553_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1164\/rccm.201610-2088OC","volume":"196","author":"S Petrovski","year":"2017","unstructured":"Petrovski, S. et al. An Exome Sequencing Study to Assess the Role of Rare Genetic Variation in Pulmonary Fibrosis. Am. J. Respir Crit. Care Med. 196, 82\u201393. https:\/\/doi.org\/10.1164\/rccm.201610-2088OC (2017).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"55553_CR9","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi, L. et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2071\u20132082. https:\/\/doi.org\/10.1056\/NEJMoa1402584 (2014).","journal-title":"N. Engl. J. Med."},{"key":"55553_CR10","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King, T. E. Jr. et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 370, 2083\u20132092. https:\/\/doi.org\/10.1056\/NEJMoa1402582 (2014).","journal-title":"N. Engl. J. Med."},{"key":"55553_CR11","doi-asserted-by":"publisher","first-page":"e54268","DOI":"10.7759\/cureus.54268","volume":"16","author":"RK Man","year":"2024","unstructured":"Man, R. K. et al. A Comparison of the Effectiveness of Nintedanib and Pirfenidone in Treating Idiopathic Pulmonary Fibrosis: A Systematic Review. Cureus 16, e54268. https:\/\/doi.org\/10.7759\/cureus.54268 (2024).","journal-title":"Cureus"},{"key":"55553_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1164\/rccm.201706-1301OC","volume":"197","author":"C Vancheri","year":"2018","unstructured":"Vancheri, C. et al. Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. Am. J. Respir Crit. Care Med. 197, 356\u2013363. https:\/\/doi.org\/10.1164\/rccm.201706-1301OC (2018).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"55553_CR13","doi-asserted-by":"publisher","unstructured":"Hettiarachchi, S. U. et al. Targeted inhibition of PI3 kinase\/mTOR specifically in fibrotic lung fibroblasts suppresses pulmonary fibrosis in experimental models. Sci. Transl. Med. 12 https:\/\/doi.org\/10.1126\/scitranslmed.aay3724 (2020).","DOI":"10.1126\/scitranslmed.aay3724"},{"key":"55553_CR14","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMra1705751","volume":"378","author":"DJ Lederer","year":"2018","unstructured":"Lederer, D. J. & Martinez, F. J. Idiopathic Pulmonary Fibrosis. N. Engl. J. Med. 378, 1811\u20131823. https:\/\/doi.org\/10.1056\/NEJMra1705751 (2018).","journal-title":"N. Engl. J. Med."},{"key":"55553_CR15","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1164\/rccm.201312-2221PP","volume":"189","author":"M Selman","year":"2014","unstructured":"Selman, M. & Pardo, A. Revealing the pathogenic and aging-related mechanisms of the enigmatic idiopathic pulmonary fibrosis. an integral model. Am. J. Respir Crit. Care Med. 189, 1161\u20131172. https:\/\/doi.org\/10.1164\/rccm.201312-2221PP (2014).","journal-title":"Am. J. Respir Crit. Care Med."},{"key":"55553_CR16","doi-asserted-by":"publisher","first-page":"13051","DOI":"10.1073\/pnas.0804280105","volume":"105","author":"JK Alder","year":"2008","unstructured":"Alder, J. K. et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl. Acad. Sci. U S A. 105, 13051\u201313056. https:\/\/doi.org\/10.1073\/pnas.0804280105 (2008).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"55553_CR17","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40139-013-0017-8","volume":"1","author":"MW Moore","year":"2013","unstructured":"Moore, M. W. & Herzog, E. L. Regulation and Relevance of Myofibroblast Responses in Idiopathic Pulmonary Fibrosis. Curr. Pathobiol Rep. 1, 199\u2013208. https:\/\/doi.org\/10.1007\/s40139-013-0017-8 (2013).","journal-title":"Curr. Pathobiol Rep."},{"key":"55553_CR18","doi-asserted-by":"publisher","first-page":"12384","DOI":"10.1074\/jbc.M208544200","volume":"278","author":"VJ Thannickal","year":"2003","unstructured":"Thannickal, V. J. et al. Myofibroblast differentiation by transforming growth factor-beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. 278, 12384\u201312389. https:\/\/doi.org\/10.1074\/jbc.M208544200 (2003).","journal-title":"J. Biol. Chem."},{"key":"55553_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1165\/rcmb.2017-0252OC","volume":"58","author":"PS Bellaye","year":"2018","unstructured":"Bellaye, P. S. et al. Lysyl Oxidase-Like 1 Protein Deficiency Protects Mice from Adenoviral Transforming Growth Factor-\u03b21-induced Pulmonary Fibrosis. Am. J. Respir. Cell Mol. Biol. 58, 461\u2013470. https:\/\/doi.org\/10.1165\/rcmb.2017-0252OC (2018).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"Suppl 1","key":"55553_CR20","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1513\/AnnalsATS.201406-240MG","volume":"12","author":"ES White","year":"2015","unstructured":"White, E. S. Lung extracellular matrix and fibroblast function. Ann. Am. Thorac. Soc. 12 (Suppl 1), 30\u201333. https:\/\/doi.org\/10.1513\/AnnalsATS.201406-240MG (2015).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"55553_CR21","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1165\/rcmb.2016-0379OC","volume":"58","author":"CJ Philp","year":"2018","unstructured":"Philp, C. J. et al. Extracellular Matrix Cross-Linking Enhances Fibroblast Growth and Protects against Matrix Proteolysis in Lung Fibrosis. Am. J. Respir. Cell Mol. Biol. 58, 594\u2013603. https:\/\/doi.org\/10.1165\/rcmb.2016-0379OC (2018).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"55553_CR22","doi-asserted-by":"publisher","unstructured":"Volkmann, E. R. et al. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis. Eur. Respir Rev. 33 https:\/\/doi.org\/10.1183\/16000617.0015-2024 (2024).","DOI":"10.1183\/16000617.0015-2024"},{"key":"55553_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/ce.S76549","volume":"11","author":"GA Margaritopoulos","year":"2016","unstructured":"Margaritopoulos, G. A., Vasarmidi, E. & Antoniou, K. M. Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. Core Evid. 11, 11\u201322. https:\/\/doi.org\/10.2147\/ce.S76549 (2016).","journal-title":"Core Evid."},{"key":"55553_CR24","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.15420\/cfr.2021.30","volume":"8","author":"A Aimo","year":"2022","unstructured":"Aimo, A. et al. Pirfenidone for Idiopathic Pulmonary Fibrosis and Beyond. Card Fail. Rev. 8, e12. https:\/\/doi.org\/10.15420\/cfr.2021.30 (2022).","journal-title":"Card Fail. Rev."},{"key":"55553_CR25","doi-asserted-by":"publisher","unstructured":"Lin, A. et al. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials. Sci. Transl. Med. 11 https:\/\/doi.org\/10.1126\/scitranslmed.aaw8412 (2019).","DOI":"10.1126\/scitranslmed.aaw8412"},{"key":"55553_CR26","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2147\/dddt.S284819","volume":"15","author":"M Kato","year":"2021","unstructured":"Kato, M. et al. Clinical Significance of Continuable Treatment with Nintedanib Over 12 Months for Idiopathic Pulmonary Fibrosis in a Real-World Setting. Drug Des. Devel Ther. 15, 223\u2013230. https:\/\/doi.org\/10.2147\/dddt.S284819 (2021).","journal-title":"Drug Des. Devel Ther."},{"key":"55553_CR27","doi-asserted-by":"publisher","first-page":"205031212110233","DOI":"10.1177\/20503121211023357","volume":"9","author":"M Dobashi","year":"2021","unstructured":"Dobashi, M. et al. The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study. SAGE Open. Med. 9, 20503121211023357. https:\/\/doi.org\/10.1177\/20503121211023357 (2021).","journal-title":"SAGE Open. Med."},{"key":"55553_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/978-981-10-3233-2_4","volume":"962","author":"AD Yzaguirre","year":"2017","unstructured":"Yzaguirre, A. D., de Bruijn, M. F. & Speck, N. A. The Role of Runx1 in Embryonic Blood Cell Formation. Adv. Exp. Med. Biol. 962, 47\u201364. https:\/\/doi.org\/10.1007\/978-981-10-3233-2_4 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"55553_CR29","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.ajpath.2020.12.005","volume":"191","author":"L Gonzalez-Buendia","year":"2021","unstructured":"Gonzalez-Buendia, L. et al. Treatment of Experimental Choroidal Neovascularization via RUNX1 Inhibition. Am. J. Pathol. 191, 418\u2013424. https:\/\/doi.org\/10.1016\/j.ajpath.2020.12.005 (2021).","journal-title":"Am. J. Pathol."},{"key":"55553_CR30","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1038\/86264","volume":"8","author":"J Bravo","year":"2001","unstructured":"Bravo, J., Li, Z., Speck, N. A. & Warren, A. J. The leukemia-associated AML1 (Runx1)--CBF beta complex functions as a DNA-induced molecular clamp. Nat. Struct. Biol. 8, 371\u2013378. https:\/\/doi.org\/10.1038\/86264 (2001).","journal-title":"Nat. Struct. Biol."},{"key":"55553_CR31","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.ajpath.2021.04.006","volume":"191","author":"M O\u2019Hare","year":"2021","unstructured":"O\u2019Hare, M. et al. Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators. Am. J. Pathol. 191, 1193\u20131208. https:\/\/doi.org\/10.1016\/j.ajpath.2021.04.006 (2021).","journal-title":"Am. J. Pathol."},{"key":"55553_CR32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.pharmthera.2017.06.008","volume":"180","author":"R Malaviya","year":"2017","unstructured":"Malaviya, R., Laskin, J. D. & Laskin, D. L. Anti-TNF\u03b1 therapy in inflammatory lung diseases. Pharmacol. Ther. 180, 90\u201398. https:\/\/doi.org\/10.1016\/j.pharmthera.2017.06.008 (2017).","journal-title":"Pharmacol. Ther."},{"key":"55553_CR33","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/toxsci\/kfv161","volume":"148","author":"R Malaviya","year":"2015","unstructured":"Malaviya, R. et al. Attenuation of Nitrogen Mustard-Induced Pulmonary Injury and Fibrosis by Anti-Tumor Necrosis Factor-\u03b1 Antibody. Toxicol. Sci. 148, 71\u201388. https:\/\/doi.org\/10.1093\/toxsci\/kfv161 (2015).","journal-title":"Toxicol. Sci."},{"key":"55553_CR34","doi-asserted-by":"publisher","first-page":"14592","DOI":"10.1073\/pnas.1200037109","volume":"109","author":"L Cunningham","year":"2012","unstructured":"Cunningham, L. et al. Identification of benzodiazepine Ro5-3335 as an inhibitor of CBF leukemia through quantitative high throughput screen against RUNX1-CBF\u03b2 interaction. Proc. Natl. Acad. Sci. U S A. 109, 14592\u201314597. https:\/\/doi.org\/10.1073\/pnas.1200037109 (2012).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"55553_CR35","doi-asserted-by":"publisher","first-page":"21117","DOI":"10.1038\/s41598-022-25773-3","volume":"12","author":"ST Tsikis","year":"2022","unstructured":"Tsikis, S. T. et al. Direct thrombin inhibitors as alternatives to heparin to preserve lung growth and function in a murine model of compensatory lung growth. Sci. Rep. 12, 21117. https:\/\/doi.org\/10.1038\/s41598-022-25773-3 (2022).","journal-title":"Sci. Rep."},{"key":"55553_CR36","doi-asserted-by":"publisher","DOI":"10.3791\/54052","author":"JP Dougherty","year":"2016","unstructured":"Dougherty, J. P., Springer, D. A. & Gershengorn, M. C. The Treadmill Fatigue Test: A Simple, High-throughput Assay of Fatigue-like Behavior for the Mouse. J. Vis. Exp. https:\/\/doi.org\/10.3791\/54052 (2016).","journal-title":"J. Vis. Exp."},{"key":"55553_CR37","doi-asserted-by":"publisher","unstructured":"Zheng, Q. et al. Mortality and survival in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. ERJ Open. Res. 8 https:\/\/doi.org\/10.1183\/23120541.00591-2021 (2022).","DOI":"10.1183\/23120541.00591-2021"},{"key":"55553_CR38","doi-asserted-by":"publisher","first-page":"20554","DOI":"10.1038\/s41598-020-77254-0","volume":"10","author":"S Delgado-Tirado","year":"2020","unstructured":"Delgado-Tirado, S. et al. Topical delivery of a small molecule RUNX1 transcription factor inhibitor for the treatment of proliferative vitreoretinopathy. Sci. Rep. 10, 20554. https:\/\/doi.org\/10.1038\/s41598-020-77254-0 (2020).","journal-title":"Sci. Rep."},{"key":"55553_CR39","doi-asserted-by":"publisher","unstructured":"McDonough, J. E. et al. Transcriptional regulatory model of fibrosis progression in the human lung. JCI Insight. 4 https:\/\/doi.org\/10.1172\/jci.insight.131597 (2019).","DOI":"10.1172\/jci.insight.131597"},{"key":"55553_CR40","doi-asserted-by":"publisher","unstructured":"Sivakumar, P. et al. RNA sequencing of transplant-stage idiopathic pulmonary fibrosis lung reveals unique pathway regulation. ERJ Open. Res. 5 https:\/\/doi.org\/10.1183\/23120541.00117-2019 (2019).","DOI":"10.1183\/23120541.00117-2019"},{"key":"55553_CR41","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1165\/rcmb.2020-0546OC","volume":"65","author":"IR Konigsberg","year":"2021","unstructured":"Konigsberg, I. R. et al. Molecular Signatures of Idiopathic Pulmonary Fibrosis. Am. J. Respir. Cell Mol. Biol. 65, 430\u2013441. https:\/\/doi.org\/10.1165\/rcmb.2020-0546OC (2021).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"55553_CR42","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/s41467-020-15647-5","volume":"11","author":"T Tsukui","year":"2020","unstructured":"Tsukui, T. et al. Collagen-producing lung cell atlas identifies multiple subsets with distinct localization and relevance to fibrosis. Nat. Commun. 11, 1920. https:\/\/doi.org\/10.1038\/s41467-020-15647-5 (2020).","journal-title":"Nat. Commun."},{"key":"55553_CR43","doi-asserted-by":"publisher","first-page":"697","DOI":"10.32604\/biocell.2023.026148","volume":"47","author":"J LIU","year":"2023","unstructured":"LIU, J., WANG, F., YUAN, B. & LUO, F. Transcriptional factor RUNX1: A potential therapeutic target for fibrotic pulmonary disease. BIOCELL 47, 697\u2013705 (2023).","journal-title":"BIOCELL"},{"key":"55553_CR44","doi-asserted-by":"publisher","unstructured":"Adams, T. S. et al. Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. Sci Adv 6, eaba (1983). https:\/\/doi.org\/10.1126\/sciadv.aba1983 (2020).","DOI":"10.1126\/sciadv.aba1983"},{"key":"55553_CR45","doi-asserted-by":"publisher","first-page":"3625","DOI":"10.1016\/j.celrep.2018.03.010","volume":"22","author":"T Xie","year":"2018","unstructured":"Xie, T. et al. Single-Cell Deconvolution of Fibroblast Heterogeneity in Mouse Pulmonary Fibrosis. Cell. Rep. 22, 3625\u20133640. https:\/\/doi.org\/10.1016\/j.celrep.2018.03.010 (2018).","journal-title":"Cell. Rep."},{"key":"55553_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40139-016-0099-1","volume":"4","author":"NG Frangogiannis","year":"2016","unstructured":"Frangogiannis, N. G. Fibroblast-Extracellular Matrix Interactions in Tissue Fibrosis. Curr. Pathobiol Rep. 4, 11\u201318. https:\/\/doi.org\/10.1007\/s40139-016-0099-1 (2016).","journal-title":"Curr. Pathobiol Rep."},{"key":"55553_CR47","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41419-020-02889-w","volume":"11","author":"S Lin","year":"2020","unstructured":"Lin, S. et al. LncRNA Hoxaas3 promotes lung fibroblast activation and fibrosis by targeting miR-450b-5p to regulate Runx1. Cell. Death Dis. 11, 706. https:\/\/doi.org\/10.1038\/s41419-020-02889-w (2020).","journal-title":"Cell. Death Dis."},{"key":"55553_CR48","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/abbs\/gmx129","volume":"50","author":"X Yan","year":"2018","unstructured":"Yan, X., Xiong, X. & Chen, Y. G. Feedback regulation of TGF-\u03b2 signaling. Acta Biochim. Biophys. Sin (Shanghai). 50, 37\u201350. https:\/\/doi.org\/10.1093\/abbs\/gmx129 (2018).","journal-title":"Acta Biochim. Biophys. Sin (Shanghai)"},{"key":"55553_CR49","doi-asserted-by":"publisher","first-page":"4844","DOI":"10.1073\/pnas.96.9.4844","volume":"96","author":"NT Liberati","year":"1999","unstructured":"Liberati, N. T. et al. Smads bind directly to the Jun family of AP-1 transcription factors. Proc. Natl. Acad. Sci. U S A. 96, 4844\u20134849. https:\/\/doi.org\/10.1073\/pnas.96.9.4844 (1999).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"55553_CR50","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202001668R","author":"HAB Whitmore","year":"2020","unstructured":"Whitmore, H. A. B. et al. TNF-alpha signaling regulates RUNX1 function in endothelial cells. FASEB J. https:\/\/doi.org\/10.1096\/fj.202001668R (2020).","journal-title":"FASEB J."},{"key":"55553_CR51","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ebiom.2018.04.023","volume":"31","author":"T Zhou","year":"2018","unstructured":"Zhou, T. et al. Runt-Related Transcription Factor 1 (RUNX1) Promotes TGF-\u03b2-Induced Renal Tubular Epithelial-to-Mesenchymal Transition (EMT) and Renal Fibrosis through the PI3K Subunit p110\u03b4. EBioMedicine 31, 217\u2013225. https:\/\/doi.org\/10.1016\/j.ebiom.2018.04.023 (2018).","journal-title":"EBioMedicine"},{"key":"55553_CR52","doi-asserted-by":"publisher","unstructured":"Takehara, K. et al. Differential Discontinuation Profiles between Pirfenidone and Nintedanib in Patients with Idiopathic Pulmonary Fibrosis. Cells 11 https:\/\/doi.org\/10.3390\/cells11010143 (2022).","DOI":"10.3390\/cells11010143"},{"key":"55553_CR53","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s41392-023-01469-6","volume":"8","author":"S Shyam Sunder","year":"2023","unstructured":"Shyam Sunder, S., Sharma, U. C. & Pokharel, S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management. Signal. Transduct. Target. Ther. 8, 262. https:\/\/doi.org\/10.1038\/s41392-023-01469-6 (2023).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"55553_CR54","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1093\/infdis\/172.5.1246","volume":"172","author":"RH Haubrich","year":"1995","unstructured":"Haubrich, R. H. et al. A randomized trial of the activity and safety of Ro 24-7429 (Tat antagonist) versus nucleoside for human immunodeficiency virus infection. The AIDS Clinical Trials Group 213 Team. J. Infect. Dis. 172, 1246\u20131252. https:\/\/doi.org\/10.1093\/infdis\/172.5.1246 (1995).","journal-title":"J. Infect. Dis."},{"key":"55553_CR55","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1046\/j.1365-2613.2002.00220.x","volume":"83","author":"G Izbicki","year":"2002","unstructured":"Izbicki, G., Segel, M. J., Christensen, T. G., Conner, M. W. & Breuer, R. Time course of bleomycin-induced lung fibrosis. Int. J. Exp. Pathol. 83, 111\u2013119. https:\/\/doi.org\/10.1046\/j.1365-2613.2002.00220.x (2002).","journal-title":"Int. J. Exp. Pathol."},{"key":"55553_CR56","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.biocel.2007.08.011","volume":"40","author":"A Moeller","year":"2008","unstructured":"Moeller, A., Ask, K., Warburton, D., Gauldie, J. & Kolb, M. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int. J. Biochem. Cell Biol. 40, 362\u2013382. https:\/\/doi.org\/10.1016\/j.biocel.2007.08.011 (2008).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"55553_CR57","doi-asserted-by":"publisher","first-page":"L961","DOI":"10.1152\/ajplung.00455.2017","volume":"316","author":"S Cabrera","year":"2019","unstructured":"Cabrera, S. et al. Delayed resolution of bleomycin-induced pulmonary fibrosis in absence of MMP13 (collagenase 3). Am. J. Physiol. Lung Cell. Mol. Physiol. 316, L961\u2013l976. https:\/\/doi.org\/10.1152\/ajplung.00455.2017 (2019).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"55553_CR58","doi-asserted-by":"publisher","unstructured":"Kadam, A. H. & Schnitzer, J. E. Highly Calibrated Relationship Between Bleomycin Concentrations and Facets of the Active Phase Fibrosis in Classical Mouse Bleomycin Model. Int. J. Mol. Sci. 25 https:\/\/doi.org\/10.3390\/ijms252212300 (2024).","DOI":"10.3390\/ijms252212300"},{"key":"55553_CR59","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1165\/rcmb.2013-0094TR","volume":"49","author":"BM B","year":"2013","unstructured":"B, B. M. et al. Animal models of fibrotic lung disease. Am. J. Respir. Cell Mol. Biol. 49, 167\u2013179. https:\/\/doi.org\/10.1165\/rcmb.2013-0094TR (2013).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"55553_CR60","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3389\/fmed.2017.00118","volume":"4","author":"J Tashiro","year":"2017","unstructured":"Tashiro, J. et al. Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis. Front. Med. (Lausanne). 4, 118. https:\/\/doi.org\/10.3389\/fmed.2017.00118 (2017).","journal-title":"Front. Med. (Lausanne)"},{"key":"55553_CR61","doi-asserted-by":"publisher","first-page":"111635","DOI":"10.1016\/j.cellsig.2025.111635","volume":"128","author":"Z Zhong","year":"2025","unstructured":"Zhong, Z. et al. Nintedanib improves bleomycin-induced pulmonary fibrosis by inhibiting the Clec7a\/SPP1 pathway in interstitial macrophages. Cell. Signal. 128, 111635. https:\/\/doi.org\/10.1016\/j.cellsig.2025.111635 (2025).","journal-title":"Cell. Signal."},{"key":"55553_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.taap.2017.11.024","volume":"339","author":"O Seniutkin","year":"2018","unstructured":"Seniutkin, O. et al. Effects of pirfenidone in acute and sub-chronic liver fibrosis, and an initiation-promotion cancer model in the mouse. Toxicol. Appl. Pharmcol. 339, 1\u20139. https:\/\/doi.org\/10.1016\/j.taap.2017.11.024 (2018).","journal-title":"Toxicol. Appl. Pharmcol."},{"key":"55553_CR63","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1038\/s41390-022-02323-1","volume":"93","author":"LJ Yu","year":"2023","unstructured":"Yu, L. J. et al. Effects of systemic anticoagulation in a murine model of compensatory lung growth. Pediatr. Res. 93, 1846\u20131855. https:\/\/doi.org\/10.1038\/s41390-022-02323-1 (2023).","journal-title":"Pediatr. Res."},{"key":"55553_CR64","doi-asserted-by":"publisher","first-page":"100613","DOI":"10.1016\/j.crmeth.2023.100613","volume":"3","author":"ST Tsikis","year":"2023","unstructured":"Tsikis, S. T. et al. A pneumonectomy model to study flow-induced pulmonary hypertension and compensatory lung growth. Cell. Rep. Methods. 3, 100613. https:\/\/doi.org\/10.1016\/j.crmeth.2023.100613 (2023).","journal-title":"Cell. Rep. Methods"},{"key":"55553_CR65","doi-asserted-by":"publisher","first-page":"13158","DOI":"10.1038\/s41598-024-63670-z","volume":"14","author":"R Tonelli","year":"2024","unstructured":"Tonelli, R. et al. Stress-strain curve and elastic behavior of the fibrotic lung with usual interstitial pneumonia pattern during protective mechanical ventilation. Sci. Rep. 14, 13158. https:\/\/doi.org\/10.1038\/s41598-024-63670-z (2024).","journal-title":"Sci. Rep."},{"key":"55553_CR66","doi-asserted-by":"publisher","unstructured":"Marchioni, A. et al. Pulmonary Stretch and Lung Mechanotransduction: Implications for Progression in the Fibrotic Lung. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms22126443 (2021).","DOI":"10.3390\/ijms22126443"},{"key":"55553_CR67","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.pupt.2011.10.001","volume":"25","author":"JE Phillips","year":"2012","unstructured":"Phillips, J. E. et al. Bleomycin induced lung fibrosis increases work of breathing in the mouse. Pulm Pharmacol. Ther. 25, 281\u2013285. https:\/\/doi.org\/10.1016\/j.pupt.2011.10.001 (2012).","journal-title":"Pulm Pharmacol. Ther."},{"key":"55553_CR68","doi-asserted-by":"publisher","first-page":"e70077","DOI":"10.14814\/phy2.70077","volume":"12","author":"AG Petersen","year":"2024","unstructured":"Petersen, A. G. et al. Reproducible lung protective effects of a TGF\u03b2R1\/ALK5 inhibitor in a bleomycin-induced and spirometry-confirmed model of IPF in male mice. Physiological Rep. 12, e70077. https:\/\/doi.org\/10.14814\/phy2.70077 (2024).","journal-title":"Physiological Rep."},{"key":"55553_CR69","doi-asserted-by":"publisher","first-page":"110493","DOI":"10.1016\/j.intimp.2023.110493","volume":"121","author":"BL Ayilya","year":"2023","unstructured":"Ayilya, B. L. et al. Insights on the mechanism of bleomycin to induce lung injury and associated in vivo models: A review. Int. Immunopharmacol. 121, 110493. https:\/\/doi.org\/10.1016\/j.intimp.2023.110493 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"55553_CR70","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1183\/09031936.00183214","volume":"46","author":"FE Uhl","year":"2015","unstructured":"Uhl, F. E. et al. Preclinical validation and imaging of Wnt-induced repair in human 3D lung tissue cultures. Eur. Respir J. 46, 1150\u20131166. https:\/\/doi.org\/10.1183\/09031936.00183214 (2015).","journal-title":"Eur. Respir J."},{"key":"55553_CR71","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1007\/s00417-023-06264-1","volume":"262","author":"L Ferro Desideri","year":"2024","unstructured":"Ferro Desideri, L., Artemiev, D., Zandi, S., Zinkernagel, M. S. & Anguita, R. Proliferative vitreoretinopathy: an update on the current and emerging treatment options. Graefe\u2019s archive Clin. experimental Ophthalmol. = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 262, 679\u2013687. https:\/\/doi.org\/10.1007\/s00417-023-06264-1 (2024).","journal-title":"Graefe\u2019s archive Clin. experimental Ophthalmol. = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55553-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55553-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55553-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:03:44Z","timestamp":1786539824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-55553-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":71,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["55553"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-55553-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.A.K. is listed as an inventor in a patent for pulmonary fibrosis and coronavirus disease 2019 treatments.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25073"}}